A phase 3 randomized, open-label study evaluating the immunogenicity and safety of concomitant and staggered administration of a live, pentavalent rotavirus vaccine and an inactivated poliomyelitis vaccine in healthy infants in China-Reference-Cited by-同舟云学术

A phase 3 randomized, open-label study evaluating the immunogenicity and safety of concomitant and staggered administration of a live, pentavalent rotavirus vaccine and an inactivated poliomyelitis vaccine in healthy infants in China

Published:2024-03-20 Issue:1 Volume:20 Page:
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Chen Shaomin¹,Ying Zhifang²,Liu Yan³,Li Yuan¹,Yu Yebin⁴,Huang Meilian⁴,Huang Zhuhang¹,Ou Zhiqiang¹,Liao Yuyi¹,Zhang Yong³,Liu Guixiu⁵,Zhao Weiwei⁶,Fu Rong⁶,Shou Qiong⁶,Zheng Minghuan⁵,Liao Xueyan⁵,Tu Yingmei⁷,Stek Jon⁷,Hartzel Jonathan⁸,Li Changgui⁹,Zhang Jikai¹⁰

Affiliation:

1. Biological Products Surveillance and Evaluation, Guangdong Provincial Institute of Biological Products and Materia Medica, Guangzhou, Guangdong, China

2. Respiratory Virus Vaccine, National Institutes for Food and Drug Control, Beijing, China

3. Division of Hepatitis Virus and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, China

4. Vaccine Clinical Research Office, Yangchun Center for Disease Control and Prevention, Yangchun, Guangdong, China

5. Clinical Research, MSD Research and Development (China) Co. Ltd., Beijing, China

6. Biostatistics and Research Decision Sciences, MSD Research and Development (China) Co. Ltd., Beijing, China

7. Infectious Diseases/Vaccines Clinical Research, Merck & Co. Inc., Rahway, NJ, USA

8. Biostatistics and Research Decision Sciences, Merck & Co. Inc., Rahway, NJ, USA

9. Institute for Control of Biological Products, National Institutes for Food and Drug Control, Beijing, China

10. Directors Office, Guangdong Provincial Institute of Biological Products and Materia Medica, Guangzhou, Guangdong, China

Funder

Merck Sharp & Dohme LLC

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2024.2324538

Reference26 articles.

1. World Health Organization. Rotavirus. [accessed 2023 Sep 19]. https://www.who.int/teams/health-product-policy-and-standards/standards-and-specifications/vaccines-quality/rotavirus.

2. Rotavirus Vaccination and the Global Burden of Rotavirus Diarrhea Among Children Younger Than 5 Years

3. Rotavirus-specific and Overall Diarrhea Mortality in Chinese Children Younger than 5 Years

4. The Public Health Burden of Rotavirus Disease in Children Younger Than Five Years and Considerations for Rotavirus Vaccine Introduction in China

5. Rotavirus vaccines: WHO position paper – July 2021;World Health Organization;Wkly Epidemiol Rec